Alnylam Pharma (DUL) Q3 2019 Earnings Report
DE:DUL Q3 2019 EPS Results
- Actual EPS
- -EUR 1.72
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 2.17
DE:DUL Q3 2019 Revenue Results
- Actual Revenue
- EUR 62.64M
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- +3286.23%
Earnings Announcement Details
- Quarter
- Q3 2019
- Date
- 10/31/2019
- Time
- Before Open
- Conference Call
- Thursday, October 31, 2019
DE:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2019 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2019 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2019 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.54- | 0.73 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.4814.06 | 1.65 | 754.35% (+12.41) | |
| Jul 30, 2026 | 2026 (Q2) | 1.461.08 | -0.46 | 337.25% (+1.54) | |
| Apr 30, 2026 | 2026 (Q1) | 0.781.35 | -0.39 | 443.18% (+1.74) | |
| Feb 12, 2026 | 2025 (Q4) | 1.030.73 | -0.58 | 226.15% (+1.31) | |
| Oct 30, 2025 | 2025 (Q3) | 0.501.65 | -0.78 | 311.49% (+2.42) | |
| Jul 31, 2025 | 2025 (Q2) | -0.49-0.46 | -0.12 | -292.31% (-0.34) | |
| May 01, 2025 | 2025 (Q1) | -0.80-0.39 | -0.46 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.53-0.58 | -0.98 | 40.91% (+0.40) | |
| Oct 31, 2024 | 2024 (Q3) | -0.82-0.78 | 1.03 | -175.65% (-1.81) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
